We are live on ! Find out more
XBIO icon

Xenetic Biosciences
XBIO

12 hedge funds and large institutions have $1.22M invested in Xenetic Biosciences in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

98% more capital invested

Capital invested by funds: $615K → $1.22M (+$602K)

20% more funds holding

Funds holding: 10 → 12 (+2)

2.92% more ownership

Funds ownership: 3.45% → 6.38% (+2.9%)

Holders
12
Holders Change
+2
Holders Change %
+20%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$242K
2
Renaissance Technologies
Renaissance Technologies
New York
+$213K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$134K
4
SPIA
Steward Partners Investment Advisory
New York
+$65.8K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$47.6K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$65K

XBIO Hedge Fund Activity: Q1 2021 in Review

12 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q1 2021, worth a combined $1.22M — up 98% from $615K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new XBIO positions and 1 closed out — a net gain of 2 holders — while 6 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $242K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $65K sold.

  • 12 institutional investors held Xenetic Biosciences (XBIO) as of Q1 2021, up from 10 in Q4 2020.
  • Funds reported $1.22M of Xenetic Biosciences stock for Q1 2021, up 98% quarter-over-quarter.
  • 3 funds opened new Xenetic Biosciences positions in Q1 2021 and 1 closed out, a net change of +2 holders.
  • The largest Xenetic Biosciences buyer in Q1 2021 was Citadel Advisors, an estimated $242K added.
  • The largest Xenetic Biosciences seller in Q1 2021 was Two Sigma Securities, an estimated $65K sold.

Based on aggregated 13F filings for Q1 2021.